← Back to Clinical Trials
Recruiting NCT06611280

NCT06611280 Deuterium Metabolic Imaging in People with Multiple Sclerosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06611280
Status Recruiting
Phase
Sponsor University of Aarhus
Condition Multiple Sclerosis (MS) - Relapsing-remitting
Study Type OBSERVATIONAL
Enrollment 20 participants
Start Date 2024-10-01
Primary Completion 2025-10-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type OBSERVATIONAL
Interventions
No Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20 participants in total. It began in 2024-10-01 with a primary completion date of 2025-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this case-control study is to investigate glucose brain metabolism in people with multiple sclerosis and age- and sex-matched healthy controls. The main questions it aims to answer are: * How does brain glucose metabolism in people with multiple sclerosis compare to age- and sex-matched healthy controls? * How is the brain glucose metabolism of people with multiple sclerosis associated with disease severity? Participants will come in for testing lasting approximately three hours and undergo deuterium metabolic imaging, physical function test, cognitive function test, and answer survey.

Eligibility Criteria

Inclusion Criteria: * Aged 18-60 years. * Definite Relapsing remitting multiple sclerosis diagnosis according to the most recent diagnostic criteria Exclusion Criteria: * Contraindications for MRI: Pacemaker, neurostimulator or cholera implant. Metal foreign bodies such as fragments and irremovable piercings. Unsafe medical implants (safety of heart valves, hips and the like must be confirmed). Claustrophobia. Largest circumference including arms \> 160 cm * Pregnancy * Competing neurological, psychiatric, or systemic diseases including diabetes (except prior TIA, unspecific brain MRI findings, hypertension, atherosclerosis and hyperlipidemia/cholesterolemia which are allowed). * Participating in other clinical trials with investigational medical products or drugs.

Contact & Investigator

Central Contact

Tobias Gæmelke, PhD-stud

✉ gaemelke@ph.au.dk

📞 4528264508

Frequently Asked Questions

Who can join the NCT06611280 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Multiple Sclerosis (MS) - Relapsing-remitting. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06611280 currently recruiting?

Yes, NCT06611280 is actively recruiting participants. Contact the research team at gaemelke@ph.au.dk for enrollment information.

Where is the NCT06611280 trial being conducted?

This trial is being conducted at Aarhus C, Denmark.

Who is sponsoring the NCT06611280 clinical trial?

NCT06611280 is sponsored by University of Aarhus. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology